Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

PreOperative Endocrine Therapy for Individualised Care With Abemaciclib (POETIC-A)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04584853
Recruitment Status : Not yet recruiting
First Posted : October 14, 2020
Last Update Posted : October 14, 2020
Sponsor:
Information provided by (Responsible Party):
Institute of Cancer Research, United Kingdom

Brief Summary:
POETIC-A is a phase 3 trial which targets post-menopausal primary breast cancer patients with a high 5-year risk of relapse as determined by a high Ki67 after 2 weeks aromatase inhibitor therapy pre-surgery. Eligible patients will be randomised to standard adjuvant endocrine therapy alone or standard adjuvant endocrine therapy with a CDK4/6 inhibitor called abemaciclib.

Condition or disease Intervention/treatment Phase
Breast Cancer Female Drug: Abemaciclib Drug: Endocrine therapy Phase 3

Detailed Description:
In women with hormone sensitive early breast cancer, taking a hormone therapy (also known as endocrine therapy) for at least five years after surgery is very effective at reducing the risk of the cancer returning. However, for some women their cancer may eventually become resistant to these drugs. POETIC-A Registration part will identify those who have a higher risk of developing resistance to standard endocrine therapy (ET). 5000 - 6000 women diagnosed with early stage breast cancer and have not yet had surgery to remove the cancer will enter the Registration stage from 80 centres. Study doctors will use aromatase inhibitors (AIs), a type of ET, to treat the cancer for 2 weeks before surgery. A sample will be taken from the cancer during surgery and the study laboratory will measure a biological marker called Ki67. If the level of Ki67 does not drop after 2 weeks of AI treatment, the patient is likely to be less sensitive to endocrine therapy, and the study doctor will explore additional treatments after surgery in the POETIC-A Treatment part. Everyone who agrees to join the Treatment stage (2500 patients) will be randomly put into one of the 2 treatment groups; Group1: ET only; or Group2: ET plus a new drug called abemaciclib. The first aim of the Treatment stage is to confirm whether abemaciclib given in combination with ET is more effective than giving ET alone in preventing the cancer coming back. The study laboratory will perform a second test on the cancer sample, called an AIR-CIS test. This test aims to find out if particular groups of patients based on their tumour biology are more suitable for treatment with abemaciclib. Patients in Group 2 will receive ET plus abemaciclib for 2 years. Patients in both groups will have regular study visits during this period.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 2500 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: PreOperative Endocrine Therapy for Individualised Care With Abemaciclib
Estimated Study Start Date : November 1, 2020
Estimated Primary Completion Date : March 30, 2026
Estimated Study Completion Date : September 30, 2028

Resource links provided by the National Library of Medicine

Drug Information available for: Abemaciclib

Arm Intervention/treatment
Active Comparator: Endocrine Therapy only Drug: Endocrine therapy
Standard of care endocrine therapy for a minimum of 5 years from randomisation

Experimental: Endocrine Therapy with abemaciclib Drug: Abemaciclib
Abemaciclib used in combination with standard Endocrine Therapy for 2 years from randomisation

Drug: Endocrine therapy
Standard of care endocrine therapy for a minimum of 5 years from randomisation




Primary Outcome Measures :
  1. Time to tumour (local or distant disease) recurrence [ Time Frame: from randomisation until tumour recurrence or patient death, assessed up to 5 years ]
    the time from randomisation to local, regional or distant tumour recurrence or death from breast cancer without prior notification of relapse. Second primary cancers and intercurrent deaths will be treated as censoring events.


Secondary Outcome Measures :
  1. Relapse-free-survival [ Time Frame: from randomisation until relapse or patient death, assessed up to 5 years ]
    the time from randomisation to local, regional or distant tumour recurrence or death from any cause.

  2. Time to distant recurrence [ Time Frame: from randomisation until distant recurrence or patient death, assessed up to 5 years ]
    the time from randomisation to distant tumour recurrence. Second primary cancers and intercurrent deaths will be treated as censoring events

  3. Breast cancer specific survival [ Time Frame: from randomisation until patient death from breast cancer, assessed up to 5 years ]
    time from randomisation to death from breast cancer (with or without prior notification of relapse). Intercurrent deaths will be treated as censoring events.

  4. Overall survival [ Time Frame: from randomisation until patient death, assessed up to 5 years ]
    time from randomisation to death from any cause.

  5. Patient reported quality of life [ Time Frame: 5 years from randomisation ]
    measured using validated questionnaires which will be defined before the commencement of the relevant sub-study.

  6. Treatment related deaths [ Time Frame: 5 years from randomisation ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   No
Criteria

Registration Stage Inclusion Criteria:

1. Postmenopausal women defined as:

1a. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. However in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.

or

1b. Documented bilateral oophorectomy.

2. Diagnosed operable invasive breast cancer with a palpable tumour of any size or an estimated invasive tumour size >/=1.5cm by imaging (ultrasound/MRI/mammogram) excluding those who are grade 1 and /or lobular histological type on diagnostic biopsy.

3. Tumour ER positive and HER2 negative. ER positivity is defined as >/=1% cells staining positive (or equivalent Allred Score of ER >/=3 out of 8). HER2 negativity will be defined as per the 2018 ASCO/CAP updated guidelines.

4. Baseline Ki67 and/or clinical pathological factors which predict for a high (20%) 5-year risk of relapse with AI alone (see Appendix 2) 4a. Baseline Ki67 >/=20% measured at the local site or 4b. Presence of clinicopathologic factors that have been previously shown to predict (>50% chance) patients with Ki67 >/=8% after 2 weeks' AI, defined as one or more of the following: grade 3; clinical/radiological tumour size > 5cm; PgR negative; PgR unknown AND evidence of Vascular Invasion.

5. No evidence of metastatic spread by standard assessment according to local guidelines.

6. Written informed consent to enter the registration stage of the trial and to donation of fresh tissue.

7. No medical condition or other factor likely to preclude entry to randomised stage of the study if eligible e.g. patient would not be suitable to receive abemaciclib due to concomitant medications or medical history.

8. The patient has given written informed consent prior to any study-specific procedures and is willing and able to make herself available for the duration of the study and amenable and able to follow study schedule during treatment and follow-up and for the use of routinely collected electronic health and related records.

Registration Stage Exclusion Criteria:

  1. Men and pre/perimenopausal women.
  2. Grade 1 tumours
  3. Invasive lobular carcinoma.
  4. Concurrent use (defined as use within 4 weeks prior to diagnostic tissue sample being taken) of HRT or any other oestrogen-containing medication (including vaginal oestrogens).
  5. Prior endocrine therapy for breast cancer or breast cancer prevention.
  6. Evidence of metastatic disease.
  7. Locally advanced breast cancer not amenable to surgery.
  8. Bilateral breast cancer.
  9. Multiple unilateral tumours with different ER/PgR/HER2 status, grade or type (e.g. ductal vs lobular) i.e. anything that suggests two or more different cancers. Multifocal disease with homogenous ER/PgR/HER2 status, grade and type is allowed if at least one lesion is palpable or at least 1.5cm on ultrasound; the largest lesion should be used for sample collection and CRF completion.
  10. Previous invasive breast cancer except for ipsilateral DCIS or LCIS treated >5 years previously by locoregional therapy alone or contralateral DCIS/LCIS treated by locoregional therapy at any time.
  11. Any invasive malignancy diagnosed within previous 5 years (other than non-melanoma skin cancer or cervical carcinoma in situ).
  12. Any other medical condition likely to exclude the patient from subsequent randomisation stage. (See exclusion criteria: Eligibility for Randomisation).

Randomisation stage Inclusion Criteria

  1. Patient previously consented and registered for screening component of POETIC A.
  2. Centrally confirmed Ki67 >/=8% following 2 weeks of AI.
  3. Aromatase Inhibitor Resistant-CDK4/6 Inhibitor Sensitive (AIR-CIS) signature has been derived in the central laboratory and confirmed to ICR-CTSU.
  4. Patient must have undergone definitive surgery for the primary breast tumour with clear radial margins as judged by the multidisciplinary team.
  5. Surgical staging of the axilla must have been undertaken by sentinel node biopsy, axillary sampling or dissection.
  6. Adjuvant chemotherapy, if prescribed, must have been completed prior to randomisation and patients must have recovered (Common Terminology Criteria for Adverse Events, version 5 [CTCAEv5] Grade </=1) from the acute effects of chemotherapy except for residual alopecia or Grade 2 peripheral neuropathy prior to randomisation. A washout period of a minimum of 28 days from day 1 of last cycle of treatment is required.
  7. Adjuvant radiotherapy, if prescribed, must have been completed prior to randomisation, and patients must have recovered (Grade </=1) from the acute effects of radiotherapy. A washout period of at least 14 days is required between end of radiotherapy and randomisation.
  8. The patient should be randomised within 6 months of commencement of adjuvant endocrine therapy.
  9. The patient is able to swallow oral medications.
  10. The patient has adequate organ function for all of the following criteria defined as; ANC >/= 1.5 × 109/L (G-CSF cannot be administered to meet this ANC eligibility criterion) Platelets >/= 100 × 109/L Haemoglobin >/= 8g/dL (Blood transfusions cannot be administered to meet this haemoglobin eligibility criterion) Total bilirubin </= 1.5 × ULN (Patients with Gilbert's syndrome with a total bilirubin ≤2.0 times ULN and direct bilirubin within normal limits are permitted.) ALT and AST </= 3 × ULN
  11. The patient intends to take adjuvant endocrine therapy for at least 5 years.
  12. The patient has given written informed consent prior to any study-specific procedures (for the randomised intervention stage), willing to donate tissue from diagnostic biopsy, and is willing and able to make herself available for the duration of the study and to follow study schedule during treatment and follow-up and for the use of routinely collected electronic health and related records.

Randomisation stage Exclusion Criteria

  1. Patient has received prior CDK4/6 inhibitor.
  2. Any patient with a history of VTE (for example, DVT of the leg or arm and/or PE) will be excluded. Patients with a history of venous catheter occlusion by thrombus that did NOT surround the catheter, and the lumen could be made patent by appropriate measures (for example, saline or thrombolytic agent), are not excluded.
  3. The patient has a serious/or uncontrolled pre-existing medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (such as severe renal impairment, [for example, estimated creatinine clearance <30 mL/min], interstitial lung disease, severe dyspnoea at rest or requiring oxygen therapy, history of major surgical resection involving the stomach or small bowel, or pre-existing Crohn's disease or ulcerative colitis or a pre-existing chronic condition resulting in baseline Grade 2 diarrhoea).
  4. The patient has a personal history of any of the following conditions: syncope of cardiovascular aetiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest. Exception: patients with controlled atrial fibrillation diagnosed more than 30 days prior to randomisation are eligible.
  5. The patient has active systemic bacterial infections (requiring IV antibiotics at time of initiating study treatment), systemic fungal infection or detectable viral infection (such as known HIV positivity or with known active hepatitis B or C (e.g. hepatitis B surface antigen positive). Screening is not required for enrolment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04584853


Contacts
Layout table for location contacts
Contact: Peter Chatfield +44(0)2087224264 poetic-a-icrctsu@icr.ac.uk

Locations
Layout table for location information
United Kingdom
Royal Marsden NHS Foundation Trust
London, United Kingdom
Sponsors and Collaborators
Institute of Cancer Research, United Kingdom
Investigators
Layout table for investigator information
Principal Investigator: Stephen Johnston Royal Marsden NHS Foundation Trust
Layout table for additonal information
Responsible Party: Institute of Cancer Research, United Kingdom
ClinicalTrials.gov Identifier: NCT04584853    
Other Study ID Numbers: ICRCTSU/2019/10068
First Posted: October 14, 2020    Key Record Dates
Last Update Posted: October 14, 2020
Last Verified: October 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Institute of Cancer Research, United Kingdom:
CDK4/6 inhibitor
ER+
HER2-